These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26952542)

  • 1. Role of nanotechnology in HIV/AIDS vaccine development.
    Liu Y; Chen C
    Adv Drug Deliv Rev; 2016 Aug; 103():76-89. PubMed ID: 26952542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of biodegradable nanomaterials and applications in vaccines.
    Yan X; Zhou M; Yu S; Jin Z; Zhao K
    Vaccine; 2020 Jan; 38(5):1096-1104. PubMed ID: 31813649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of nanomaterials as vaccine adjuvants.
    Zhu M; Wang R; Nie G
    Hum Vaccin Immunother; 2014; 10(9):2761-74. PubMed ID: 25483497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives.
    Zeng Y; Zou F; Xia N; Li S
    Expert Rev Vaccines; 2023; 22(1):681-695. PubMed ID: 37496496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology and HIV: potential applications for treatment and prevention.
    Kim PS; Read SW
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(6):693-702. PubMed ID: 20860050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.
    Date AA; Destache CJ
    Biomaterials; 2013 Aug; 34(26):6202-28. PubMed ID: 23726227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-Delivery Vehicles/Adjuvants for DNA Vaccination Against HIV.
    Dong Y; Yang J; Zhang J; Zhang X
    J Nanosci Nanotechnol; 2016 Mar; 16(3):2126-33. PubMed ID: 27455611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.
    Ross AL; Bråve A; Scarlatti G; Manrique A; Buonaguro L
    Lancet Infect Dis; 2010 May; 10(5):305-16. PubMed ID: 20417413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition.
    Singh A; Permar S; Kollmann TR; Levy O; Marovich M; De Paris K
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31315966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Maginot Line and AIDS vaccines.
    Stricker RB; Goldberg B
    Med Hypotheses; 1997 Jun; 48(6):527-9. PubMed ID: 9247898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
    Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and opportunities for development of an AIDS vaccine.
    Nabel GJ
    Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of adjuvants in retroviral vaccines.
    Vogel FR
    Int J Immunopharmacol; 1995 Feb; 17(2):85-90. PubMed ID: 7657411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant.
    Li M; Jiang Y; Gong T; Zhang Z; Sun X
    Mol Pharm; 2016 Mar; 13(3):885-94. PubMed ID: 26824411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in vaccine adjuvants for infectious diseases.
    Singh M; Srivastava I
    Curr HIV Res; 2003 Jul; 1(3):309-20. PubMed ID: 15046255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of targeted adjuvants for HIV-1 vaccines.
    Liu J; Ostrowski M
    AIDS Res Ther; 2017 Sep; 14(1):43. PubMed ID: 28893282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of vaccine adjuvants using polymeric nanoparticles and their potential applications for anti-HIV vaccine].
    Akagi T; Baba M; Akashi M
    Yakugaku Zasshi; 2007 Feb; 127(2):307-17. PubMed ID: 17268151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review.
    Feng X; Shi Y; Zhang Y; Lei F; Ren R; Tang X
    Int J Nanomedicine; 2024; 19():1509-1538. PubMed ID: 38384321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination.
    Glass JJ; Kent SJ; De Rose R
    Expert Rev Vaccines; 2016 Jun; 15(6):719-29. PubMed ID: 26783186
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.